Get the Stockscreener App
4.64
1.49%
-0.07
After Hours:
4.62
-0.02
-0.43%
Annexon Inc stock is traded at $4.64, with a volume of 2.90M.
It is down -1.49% in the last 24 hours and down -10.94% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$4.71
Open:
$4.8
24h Volume:
2.90M
Relative Volume:
1.13
Market Cap:
$760.23M
Revenue:
-
Net Income/Loss:
$-196.48M
P/E Ratio:
-3.8164
EPS:
-1.2158
Net Cash Flow:
$-183.16M
1W Performance:
-9.38%
1M Performance:
-10.94%
6M Performance:
-5.50%
1Y Performance:
+86.35%
1-Day Range:
$4.47
$4.94
1-Week Range:
$4.47
$5.34
52-Week Range:
$1.85
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.64 | 771.70M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (ANNX) director William Waddill receives 65,000 stock options grant - Stock Titan
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant - Stock Titan
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70 - Stock Titan
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares - Stock Titan
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEarnings Sentiment Score - newsline.com
ANNX News | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Stockholders Approve Directors, Compensation and Share Increase - TipRanks
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes - Stock Titan
Annexon Inc. (ANNX) Gains 2.13% as Biotech Stock Holds Above Key SupportCounter Trend Trade - newsline.com
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027 - TradingView
Annexon Inc Annual Shareholders Meeting Transcript - GuruFocus
Annexon eyes 'win season' with Q4 vision trial data, GBS filings ahead - MSN
Annexon maps 3 big pipeline catalysts ahead of Q4 vision-drug readout - MSN
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead - MarketBeat
Annexon Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
ANNX Stock Price, Quote & Chart - ChartMill
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - sharewise.com
ANNX: Three major clinical data readouts expected in 2024, each with strong differentiation - TradingView
Annexon Inc. (ANNX) Holds Steady Near Support as Consolidation ContinuesBeta Neutral Pair - newsline.com
ANNX Q1 2026 Earnings: EPS Beat Guidance as Clinical Progress ContinuesSubscription Growth Report - The Legal Advocate
Annexon(ANNX.US) Director Buys US$3.32 Million in Common Stock - Moomoo
Annexon Inc. (ANNX) Shows Modest Gain: Biotech Stock Tests Key LevelsWide Range Bar - The Legal Advocate
Insider Purchase: Director at $ANNX Buys 613,497 Shares - Moomoo
Annexon director Muneer Satter buys $3.3m in common stock By Investing.com - Investing.com South Africa
Annexon director Muneer Satter buys $3.3m in common stock - Investing.com
Director-linked fund buys 613K Annexon (ANNX) shares in open market - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageCFO Commentary Report - The Legal Advocate
ANNX Q1 2026 Earnings: EPS Surpasses Estimates by 22% as Biotech Advances PipelineEarnings Preview - The Legal Advocate
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing - Moomoo
ANNX Q1 2026 Earnings: EPS Beat Surprise as Clinical-Stage Biotech Tightens Cost ControlPost-Earnings Drift - newsline.com
Annexon to Participate in Upcoming June Investor Conferences - Investing News Network
Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Lifts Shares as Pre-Revenue Biotech AdvancesEarnings Revision Report - newsline.com
ANNX Q1 2026 Earnings: Clinical Pipeline Progress Drives EPS Beat as Stock Dips on Broader Biotech HeadwindsGuidance Accuracy Score - newsline.com
Annexon Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Redmile Group, LLC's Annexon Inc(ANNX) Holding History - GuruFocus
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Moomoo
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%) - Stock Titan
What Annexon (ANNX)'s -2.61% Decline Means for Investors 2026-05-15Pullback Trade - newsline.com
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Annexon, Inc.common stock (NQ: ANNX - FinancialContent
Annexon Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference - sharewise.com
Director William Carson Acquires Additional Shares of Annexon In - GuruFocus
Director adds Annexon (ANNX) shares in Rule 10b5-1 plan purchase - Stock Titan
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):